KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

Zhihua Ran, Yan Chen, Yinglei Miao, Yufang Wang, Xiang Gao, Jie Zhong, Xueli Ding, Chengdang Wang, Xiaolan Zhang, Yijuan Ding, Naizhong Hu, Dan Tang, Jiao Yu, Chenxi Qian, Jun Shen

BioDrugs 40(4) 733-745

PMID42120652
PMCIDPMC13337950
DOI10.1007/s40259-026-00776-y
发表日期2026-05-12
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。
摘要

摘要

BACKGROUND: Mirikizumab, a p19-directed anti-interleukin-23 antibody, demonstrated efficacy in patients with moderately-to-severely active ulcerative colitis in the global phase 3 LUCENT-1 induction (NCT03518086) and LUCENT-2 maintenance (NCT03524092) trials. OBJECTIVE: The aim was to conduct a pre-specified Chinese subpopulation analysis of LUCENT-1 and LUCENT-2. METHODS: In LUCENT-1, patients were randomized 3:1 to mirikizumab 300 mg or placebo intravenously every 4 weeks (Q4W) for 12 weeks. In LUCENT-2, patients with a clinical response to mirikizumab at week 12 of LUCENT-1 were re-randomized 2:1 to mirikizumab 200 mg or placebo via subcutaneous injection Q4W for 40 weeks. The primary endpoint in both trials was clinical remission at study end, defined as a Mayo stool frequency subscore of 0, or 1 with a ≥ 1-point decrease from baseline, rectal bleeding subscore of 0, and an endoscopic subscore of 0 or 1 (excluding friability). RESULTS: Among 183 Chinese patients included in the LUCENT-1 induction trial, clinical remission rates at week 12 were higher with mirikizumab 300 mg (n = 140) versus placebo (n = 43) (18.6% vs. 7.0%; common risk difference 11.5%). Among 80 patients who responded to mirikizumab and underwent randomization again in the LUCENT-2 maintenance trial, clinical remission rates at week 40 were higher with mirikizumab 200 mg (n = 56) versus placebo (n = 24) (50.0% vs. 12.5%; common risk difference 40.4%). During induction and maintenance, the incidence of adverse events was comparable between the mirikizumab and placebo groups. CONCLUSIONS: Mirikizumab was effective and well tolerated in the subpopulation of Chinese patients with moderately-to-severely active ulcerative colitis, consistent with the overall trial population. TRIAL REGISTRATIONS: Clinicaltrials.gov (NCT03518086 and NCT03524092).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 a LUCENT-1 and b LUCENT-2 patient flow diagrams (Chinese patients). AE adverse event, IV intravenous, Miri mirikizumab, mITT modified intent-to-treat, SC subcutaneous
非 KM Figure
Fig. 2Fig. 2 Primary and key secondary endpoints in the induction period (Chinese patients from LUCENT-1): a clinical remission, alternate clinical remission, clinical response, endoscopic remission, and HEMI at week 12; b symptomatic remission at week 4 and 12; c change in bowel urgency from baseline at week 12. Error bars represent 95% CI. ∆ common risk difference (95% CI), CI confidence interval, HEMI histologic–endoscopic mucosal improvement, IV intravenous, LSM least squares mean, NRS numeric rating scale
非 KM Figure
Fig. 3Fig. 3 Primary and key secondary endpoints in the maintenance period (Chinese patients from LUCENT-2): a clinical remission, alternate clinical remission, corticosteroid-free remission, maintenance of clinical remission, and bowel urgency remission at week 40; b endoscopic-related endpoints at week 40; c change in bowel urgency from baseline at week 40. In LUCENT-2, patients with a response to Miri induction therapy from LUCENT-1 were randomly assigned to receive 200 mg of Miri or placebo subcutaneously. Maintenance of clinical remission was defined among patients achieving clinical remission by end of the induction trial. Bowel urgency remission was defined among patients with a baseline urgency NRS ≥ 3. Error bars represent 95% CI. ∆ common risk difference (95% CI), CI confidence interval, IV intravenous, LSM least squares mean, Miri mirikizumab, NRS numeric rating scale, SC subcutaneous
非 KM Figure